Nitrate tolerance impairs nitric oxide-mediated vasodilation in vivo

Cardiovascular Research

Volumn 31, Issue 5, 1996, Pages 814-819

  Laursen, Jørn Bech ^a,b   Boesgaard, Søren ^a   Poulsen, Henrik Enghusen ^a   Aldershvile, Jan ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b University of Copenhagen   (Denmark)

Author keywords

Acetylcholine; L NAME; N acetylcysteine; Nitrate tolerance; Nitrates; Nitric oxide; Rat, anesthetized

Indexed keywords

ACETYLCHOLINE; ACETYLCYSTEINE; GLYCERYL TRINITRATE; N(G) NITROARGININE METHYL ESTER; NITROPRUSSIDE SODIUM;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG TOLERANCE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; VASODILATATION;

ACETYLCHOLINE; ACETYLCYSTEINE; ANIMALS; ARGININE; DRUG TOLERANCE; FEMALE; NG-NITROARGININE METHYL ESTER; NITRATES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROGLYCERIN; NITROPRUSSIDE; RATS; RATS, WISTAR; VASODILATION;

EID: 0029997902     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/0008-6363(96)00027-2     Document Type: Article

References (47)

1. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, Gruetter CA. Mechanisms of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide. Evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981;218:739-749.
2. Chung SJ, Fung HL. Relationship between nitroglycerin-induced vascular relaxation and nitric oxide production. Biochem Pharmacol 1993;45:157-163.
3. Thadani U, Fung HL, Darke AC, Parker JO. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action and dose-response relation during acute and sustained therapy. Am J Cardiol 1982;49:411-419.
4. Zimrin D, Reichek N, Bogin KT, Aurigemma G, Douglas P, Berko B, Fung HL. Antianginal effects of intravenous nitroglycerin over 24 hours. Circulation 1988;77:1376-1384.
5. Boesgaard S, Aldershvile J, Poulsen HE. Preventive administration of intravenous N-acetylcysteine and development of tolerance to isosorbide dinitrate in patients with angina pectoris. Circulation 1992;85:143-149.
6. Slack CJ, McLaughlin BE, Nakatsu K, Marks GS, Brien JF. Nitric oxide-induced vasodilation of organic nitrate-tolerant rabbit aorta. Can J Physiol Pharmacol 1988;66:1344-1346.
7. Förster S, Woditsch I, Schröder H, Schrör K. Reduced nitric oxide release causes nitrate tolerance in the intact coronary circulation. J Cardiovasc Pharmacol 1991;17:867-872.
8. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987;317:799-804.
9. Parker JD, Farrell B, Fenton T, Cohanim M, Parker JO. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation 1991;84:2336-2345.
10. Münzel T, Sayegh H, Harrison DG. Nitroglycerin tolerance is associated with increases in vascular constriction mediated by protein kinase C. Circulation 1994;90(abstr):1720.
11. Axelsson KL, Andersson RGG. Tolerance towards nitroglycerin, induced in vivo, is correlated to a reduced cGMP response and alterations in cGMP turnover. Eur J Pharmacol 1983;88:71-79.
12. Waldmann SA, Rapoport RM, Ginsburg R, Murad F. Desensitization to nitroglycerin in vascular smooth muscle from rat and human. Biochem Pharmacol 1986;35:3525-3531.
13. Münzel T, Sayegh H, Freeman BA, Tarpey M, Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. J Clin Invest 1995;95:187-194.
14. Buga GM, Griscavage JM, Rogers NE, Ignarro LJ, Negative feedback regulation of endothelial cell function by nitric oxide. Circ Res 1993;73:808-812.
15. Torresi JT, Horowitz JD, Dusting GJ. Prevention and reversal of tolerance to nitroglycerine with N-acetylcysteine. J Cardiovasc Pharmacol 1985;7:777-783.
16. Needleman P, Jakschik B, Johnson EM. Sulfhydryl requirement for relaxation of vascular smooth muscle. J Pharmacol Exp Ther 1973;187:324-331.
17. Feelisch M, Noack EA. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 1987;139:19-30.
18. Chong S, Fung HL. Biochemical and pharmacological interactions between nitroglycerin and thiols. Biochem Pharmacol 1991;42:1433-1439.
19. May DC, Popma JJ, Black WH, Schaeffer S, Lee HR, Levine BD, Hillis LD. In vivo induction and reversal of nitroglycerin tolerance in human coronary arteries. N Engl J Med 1987;317:805-809.
20. Boesgaard S, Iversen H, Wroblewski H, Poulsen HE, Frandsen H, Kastrup J, Aldershvile J. Altered peripheral vasodilatory profile of nitroglycerin during long-term infusion of N-acetylcysteine. J Am Coll Cardiol 1994;23:163-169.
21. Boesgaard S, Aldershvile J, Poulsen HE, Loft S, Anderson ME, Meister A. Nitrate tolerance in vivo is not associated with depletion of arterial or venous thiol levels. Circ Res 1994;74:115-120.
22. Palmer RMJ, Ashton D, Moncada S. Vascular endothelial cells synthesise nitric oxide from L-arginine. Nature 1988;333:664-666.
23. Moncada S, Higgs EA. Endogenous nitric oxide: physiology, pathology and clinical relevance. Eur J Clin Pharmacol 1991;21:361-374.
24. Rapoport RM, Murad F. Agonist-induced endothelium-dependent relaxation in rat thoracic aorta may be mediated through cyclic guanosine monophosphate. Circ Res 1983;52:352-357.
25. Kowaluk EA, Poliszcuk R, Fung HL. Tolerance to relaxation in rat aorta: comparison of an S-nitrosothiol with nitroglycerin. Eur J Pharmacol 1987;144:379-383.
26. Voorde JV, Vanheel B, Leusen I. Influence of vascular tolerance to nitroglycerin on endothelium-dependent relaxation. Arch Int Pharmacodyn 1987;290:215-221.
27. Mülsch A, Busse R, Bassenge E. Desensitization of guanylate cyclase in nitrate tolerance does not impair endothelium-dependent responses. Eur J Pharmacol 1988;158:191-198.
28. Mülsch A, Busse R, Winter I, Bassenge E. Endothelium-and sydnonimine-induced responses of native and cultured aortic smooth muscle cells are not impaired by nitroglycerin tolerance. Naunyn-Schmiedebergs's Arch Pharmacol 1989;339:568-574.
29. Lawson DL, Nichols WW, Mehta P, Metha JL. Captopril-induced reversal of nitroglycerin tolerance: role of sulfhydryl group vs ACE-inhibitory activity. J Cardiovasc Pharmacol 1991;17:411-418.
30. Kukovetz WR, Holzmann S. Mechanism of nitrate-induced vasodilation and tolerance. Z Cardiol 1983;72(suppl 3):14-19.
31. Rapoport RM, Waldman SA, Ginsburg R, Molina CR, Murad F. Effects of glyceryl trinitrate on endothelium-dependent and -independent relaxation and cyclic GMP levels in rat aorta and human coronary artery. J Cardiovasc Pharmacol 1987;10:82-89.
32. Molina CR, Andresen JW, Rapoport RM, Waldman S, Murad F. Effect of in vivo nitroglycerin therapy on endothelium-dependent and independent vascular relaxation and cyclic guanosine monophosphate accumulation in rat aorta. J Cardiovasc Pharmacol 1987;10:371-378.
33. Schröder H, Leitman DC, Bennett BM, Waldnamn SA, Murad F. Glyceryl trinitrate-induced desenitization of guanylate cyclase cyclase in cultured rat lung fibroblasts. J Pharmacol Exp Ther 1988;245:413-418.
34. Boesgaard S, Poulsen HE, Aldershvile J, Loft S, Anderson ME, Meister A. Acute effects of nitroglycerin depend on both plasma and intracellular sulfhydryl compound levels in vivo. Effect of agents with different sulfhydryl modulating properties. Circulation 1993;87:547-553.
35. Fukazawa M, Namiki A. Reduced endothelium-dependent vasodilation by acetylcholine and bradykinin in isolated nitroglycerin-tolerant blood vessels. Gen Pharmac 1994;25:61-67.
36. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature (Lond) 1986;320:454-456.
37. Horowitz JD, Antman EM, Lorell BH, Barry WH, Smith TW. Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine. Circulation 1983;68:1247-1253.
38. Fung HL, Chong S, Kowaluk E, Hough K, Kakemi M. Mechanisms for the pharmacologic interaction of organic nitrates with thiols. Existence of an extracellular pathway for the reversal of nitrate vascular tolerance by N-acetylcysteine. J Pharmacol Exp Ther 1988;245:524-530.
39. Gruetter CA, Lemke SM. Dissociation of cysteine and glutathione levels from nitroglycerin-induced relaxation. Eur J Pharmacol 1985;111:85-95.
40. Henry PJ, Horowitz JD, Louis WJ. Determinants of in vitro nitroglycerin tolerance induction and reversal: influence of dose regimen, nitrate-free period, and sulfhydryl supplementation. J Cardiovasc Pharmacol 1989;14:31-37.
41. Sellke FW, Tomanek RJ, Harrison DG. L-cysteine selectively potentiates nitroglycerin-induced dilation of small coronary microvessels. J Pharm Exp Ther 1991;258:365-369.
42. Harrison DG, Bates JN. The nitrovasodilators: new ideas about old drugs. Circulation 1993;87:652-659.
43. Myers PR, Minor RL, Guerra R, Bates JN, Harrison DG. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide. Nature 1990;345:161-163.
44. Kurz MA, Lamping KG, Bates JN, Eastham CL, Marcus ML, Harrison DG. Mechanisms responsible for the heterogeneous coronary microvascular response to nitroglycerin. Circ Res 1991;68:847-855.
45. Laursen JB, Boesgaard S, Poulsen HE, Aldershvile J. Vitamin C and thiol supplementation potentiate receptor stimulated nitric oxide release in vivo. Circulation 1994;90(abstr):1301.
46. Stamler J, Mendelsohn ME, Amarante P, et al. N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res 1989;65:789-795.
47. Cooke JP, Stamler J, Andon N, Davies PF, McKinley G, Loscalzo J. Flow stimulates endothelial cells to release a nitrovasodilator that is potentiated by reduced thiol. Am J Physiol 1990;259:H804-H812.